RxDoctor Payments Data

Marcella Lindstrom, APRN

Family · Bloomington, ILNPI 1730175712

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,175 of the $65,401 with a category attached, or 72.1%. 16 manufacturers reported payments, led by Gilead at 51.8% of the total. 2025 is the largest year on record at $28,016, 6.3 times the $4,459 reported in 2021. Among family clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,401in general payments, 2019–2025

Across 178 payments — averaging $367.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$34K
  • Madrigal Pharmaceuticals$27K
  • AbbVie$3K
  • Sanofi$576
  • Novo Nordisk$173
  • Phathom Pharmaceuticals, Inc.$142
  • plus $774 from 10 others

What the payments were for

  • Consulting fees$9811%
  • Speaking & faculty fees$47,17572%
  • Travel & lodging$12,07618%
  • Food & beverage$5,0848%
  • Education$850%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,401 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$25,824
Medicare patients
159
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide19$19,123
ZenpepLipase/Protease/Amylase11$8,079
Pantoprazole Sodium283$3,554
Ursodiol20$3,119
Omeprazole164$2,865
Colestipol Hcl40$2,812
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,191
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$955
Dicyclomine Hcl42$890
Sucralfate29$727
Ondansetron OdtOndansetron25$616
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg21$545
Lansoprazole13$435
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl19$287
Famotidine19$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,533$19,12319 claims
Aimmune Therapeutics, Inc.Zenpep$115$8,07911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Bloomington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →